Results 51 to 60 of about 2,106 (155)

Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study

BMC Nephrology, 2011
Background Macrocytosis occurs in chronic hemodialysis (CHD) patients; however, its significance is unknown. The purpose of this study was to establish the prevalence and distribution of macrocytosis, to identify its clinical associations and to ...
West Kenneth A, Soroka Steven D, Tennankore Karthik K, Kiberd Bryce A   +3 more
doaj   +1 more source

Evaluating Economic and Clinical Impacts of Anaemia Management Strategies: A Systematic Review of the Evidence From the UK Perspective

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Background Anaemia significantly affects health outcomes and quality of life. While blood transfusion remains a common intervention, alternative treatments, such as iron supplementation and erythropoiesis‐stimulating agents (ESAs), offer potential to mitigate transfusion‐associated costs.
Hiro Farabi, Florian Tomini, Hayley Evans, Michael F. Murphy, Laura Green, Paula Dhiman, Gianluca Fabiano, Antony J. R. Palmer, Linda von Neree, Simon J. Stanworth   +9 more
wiley   +1 more source

How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome

British Journal of Haematology, Volume 207, Issue 1, Page 15-26, July 2025.
Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley   +1 more source

Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease

Saudi Journal of Kidney Diseases and Transplantation, 2016
The anemia of chronic kidney disease (CKD) is a common comorbidity seen in kidney diseases. It is also associated with increased cardiovascular morbidity and mortality and diminished quality of life.
Fatma Al Raisi, Issa Al Salmi, Pramod Kamble, Muna Al Shehri, Faissal A. M. Shaheen   +4 more
doaj  

A Rare Case of Parvovirus Infection Causing Pure Red Cell Aplasia in a Kidney‐Pancreas Transplant Recipient

Nephrology, Volume 30, Issue 7, July 2025.
ABSTRACT Parvovirus B19 infection can rarely manifest with pure red cell aplasia in immunocompromised hosts. This case details a 48‐year‐old male, 11 years post kidney‐pancreas transplant who was admitted with a chronic normocytic anaemia (haemoglobin 72 g/L) after being admitted four months prior with a bleeding peptic ulcer, requiring eight units of ...
Oscar Perry, Robert Ellis, Sanjana Dang, George T. John, Stephanie Hendry, Monica Suet Ying Ng   +5 more
wiley   +1 more source

The use of darbepoetin alpha in infants

Сеченовский вестник, 2019
Among the somatic pathology in young children, the most common is anemic syndrome. Until recently, the commonest method for correction of anemia was hemotransfusion, which allows to restore normal hemoglobin quickly, but has the high risk of ...
A. V. Shchegolev, G. Z. Sufianova, A. A. Sufianov, N. E. Ivanova, M. S. Khlestkina   +4 more
doaj   +1 more source

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability

International Journal of Nephrology and Renovascular Disease, 2014
Javier Arrieta,1 Iñigo Moina,1 José Molina,2 Isabel Gallardo,3 María Luisa Muñiz,4 Carmen Robledo,5 Oscar García,5 Fernando Vidaur,6 Rosa Inés Muñoz,3 Izaskun Iribar,7 Román Aguirre,7 Antonio Maza8 ...
Arrieta J, Moina I, Molina J, Gallardo I, Muñiz ML, Robledo C, García O, Vidaur F, Muñoz RI, Iribar I, Aguirre R, Maza A   +11 more
doaj  

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

BMC Nephrology, 2019
Background Darbepoetin alfa (DA-α) is a long-acting erythropoiesis-stimulating glycoprotein which has half-life three-fold longer than that of Erythropoietin alfa (EPO). The objective of this study was to compare the efficacy and safety of DA-α injection
Shubhadeep D. Sinha, Vamsi Krishna Bandi, Bala Reddy Bheemareddy, Pankaj Thakur, Sreenivasa Chary, Kalpana Mehta, Vikranth Reddy Pinnamareddy, Rajendra Pandey, Subhramanyam Sreepada, Santosh Durugkar   +9 more
doaj   +1 more source

Pharmacoeconomic analysis of using the darbepoetin alfa to correct anemia in patients with chronic renal failure who are on hemodialysis or peritoneal dialysis

Качественная клиническая практика, 2018
Goal: to conduct pharmacoeconomic analysis of using the darbepoetin alfa (Aranesp) and other erythropoiesis-stimulating agents for anemia correction in patients on hemodialysis or peritoneal dialysis. Methodology.
I. S. Krysanov, T. S. Fakeeva, O. N. Kotenko   +2 more
doaj  

Protective effects of Tadalafil and darbepoetin against ischemia - reperfusion injury in a rat testicular torsion model

International Brazilian Journal of Urology
Objectives: To evaluate protective effects of darbepoetin and tadalafil against ischemia-reperfusion injury in ipsilateral and contralateral testicle. Materials and Methods: Thirty 3-month-old adult male Wistar-Albino rats were randomly divided into 5 ...
Caglar Yildirim, Ozgur H. Yuksel, Ahmet Urkmez, Aytac Sahin, Adnan Somay, Ayhan Verit   +5 more
doaj   +1 more source